Target tyrosine kinases / Inhibit Bcr-Abl / Toxicity
STIs that target Bcr-Abl: DASATINIB, IMATINIB, NILOTINIB
Toxicity
FOR STIs generally:
- relatively minor side effects (esp. compared to conventional therapies that work by preventing rapid cell growth): nausea, vomiting, fatigue, myalgia, diarrhea, skin rashes and acne, drug interactions
- can cause congestive heart failure and decreased left ventricular ejection fraction (causing shortness of breath, palpitations, fatigue) and/or myocardial infarction
- incidence and severity vary widely within STIs
- more common and more severe with DASATINIB, IMATINIB and NILOTINIB, because Abl tyrosine kinases are necessary for maintenance of normal heart function
- incidence and severity vary widely within STIs
- teratogenic
FOR IMATINIB specifically:
- edema, bone marrow suppression